Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News — ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide 2.4 mg may not be cost-effective for secondary CVD prevention for those with overweight/obesity ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...
Two popular medications used in the fight against obesity—semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly)—are priced too high to be considered cost-effective by currently ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The United Kingdom medicines authority approved the Alzheimer’s ...
Wegovy (semaglutide) is an injectable prescription weight loss medicine that has helped people with obesity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) For those who are ...
A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...
Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...
Zanubrutinib is not cost-effective compared with bendamustine-rituximab for treatment-naive CLL in China. Despite clinical benefits, zanubrutinib's continuous administration results in higher costs, ...
Salpingectomy for permanent contraception yields an incremental cost-effectiveness ratio of $143,769 per quality-adjusted life-year (QALY) gained compared with vasectomy. The procedure prevents 6085 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback